Philogen S.p.A. (BIT:PHIL)

Market Cap	938.55M +8.2%
Revenue (ttm)	319.73M +313.8%
Net Income	229.68M +407.1%
EPS	5.70 +408.9%
Shares Out	40.28M
PE Ratio	4.09
Forward PE	n/a
Dividend	0.70 (3.00%)
Ex-Dividend Date	May 18, 2026

Volume	8,339
Open	23.30
Previous Close	23.30
Day's Range	23.15 - 23.45
52-Week Range	19.56 - 26.00
Beta	-0.02
Analysts	Buy
Price Target	27.67 (+18.5%)
Earnings Date	Sep 23, 2026

About Philogen

Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 214
• Stock Exchange: Borsa Italiana
• Ticker Symbol: PHIL

Financial Performance

In 2025, Philogen's revenue was 319.73 million, an increase of 313.81% compared to the previous year's 77.26 million. Earnings were 229.68 million, an increase of 407.10%.

Analyst Summary

According to 3 analysts, the average rating for PHIL stock is "Buy." The 12-month stock price target is €27.67, which is an increase of 18.50% from the latest price.

Price Target

€27.67

(18.50% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 17, 2026

Data Sources Report a data error